Search research articles
Contact Us
Filters
Showing results (411-420 of 703) with videos related to
Page
of 71
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2018
CD103<sup>+</sup> Tumor-Resident CD8<sup>+</sup> T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment
Jarem Edwards, James S Wilmott, Jason Madore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
A M Menzies, M T Ashworth, S Swann, et al.
Journal for Immunotherapy of Cancer
|
June 10, 2022
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
Grace Heloise Attrill, Carina N Owen, Tasnia Ahmed, et al.
Melanoma Research
|
January 3, 2020
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Victoria Atkinson, Shahneen Sandhu, Geke Hospers, et al.
JAMA Oncology
|
July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
Igor Puzanov, Antoni Ribas, Caroline Robert, et al.
Nature Reviews. Clinical Oncology
|
October 1, 2024
Two decades of advances in clinical oncology - lessons learned and future directions
Susana Banerjee, Christopher M Booth, Eduardo Bruera, et al.
Nature Communications
|
April 22, 2020
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Jenny H Lee, Elena Shklovskaya, Su Yin Lim, et al.
JCI Insight
|
September 29, 2022
Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis
Kazi J Nahar, Felix Marsh-Wakefield, Robert V Rawson, et al.
Ebiomedicine
|
August 20, 2015
The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis
Mitchell S Stark, Kerenaftali Klein, Benjamin Weide, et al.
Oncotarget
|
November 3, 2015
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
Elin S Gray, Helen Rizos, Anna L Reid, et al.
Page
of 71
Search research articles
Search
Showing results (411-420 of 703) with videos related to
Sort By:
Page
of 71
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2018
CD103<sup>+</sup> Tumor-Resident CD8<sup>+</sup> T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment
Jarem Edwards, James S Wilmott, Jason Madore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
A M Menzies, M T Ashworth, S Swann, et al.
Journal for Immunotherapy of Cancer
|
June 10, 2022
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
Grace Heloise Attrill, Carina N Owen, Tasnia Ahmed, et al.
Melanoma Research
|
January 3, 2020
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Victoria Atkinson, Shahneen Sandhu, Geke Hospers, et al.
JAMA Oncology
|
July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
Igor Puzanov, Antoni Ribas, Caroline Robert, et al.
Nature Reviews. Clinical Oncology
|
October 1, 2024
Two decades of advances in clinical oncology - lessons learned and future directions
Susana Banerjee, Christopher M Booth, Eduardo Bruera, et al.
Nature Communications
|
April 22, 2020
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Jenny H Lee, Elena Shklovskaya, Su Yin Lim, et al.
JCI Insight
|
September 29, 2022
Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis
Kazi J Nahar, Felix Marsh-Wakefield, Robert V Rawson, et al.
Ebiomedicine
|
August 20, 2015
The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis
Mitchell S Stark, Kerenaftali Klein, Benjamin Weide, et al.
Oncotarget
|
November 3, 2015
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
Elin S Gray, Helen Rizos, Anna L Reid, et al.
Page
of 71